Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Axitan is a private animal-health biotech company developing antibiotic-free products for livestock production, with a particular focus on poultry. The company's core technology is an endolysin platform that uses targeted antimicrobial enzymes to neutralize pathogenic bacteria, especially Clostridium perfringens, a key cause of necrotic enteritis in poultry. Its lead commercial product, FORC3, is a feed additive positioned as an alternative to conventional in-feed antibiotics, and the company also markets NMAN, a gel-based early-life nutrition and hydration product for chicks and poults. Axitan is expanding beyond poultry into swine, ruminant and aquaculture applications through internal development and commercial partnerships. The business sits at the intersection of biotech, animal nutrition and food-production health, aiming to improve productivity while reducing antibiotic use in animal agriculture.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Axitan.